These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10456211)

  • 1. Clinical usefulness of biochemical resorption markers in osteoporosis.
    Kyd PA; De Vooght K; Kerkhoff F; Thomas E; Fairney A
    Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():483-91. PubMed ID: 10456211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of bone alkaline phosphatase in osteoporosis.
    Kyd PA; Vooght KD; Kerkhoff F; Thomas E; Fairney A
    Ann Clin Biochem; 1998 Nov; 35 ( Pt 6)():717-25. PubMed ID: 9838984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.
    Greenspan SL; Rosen HN; Parker RA
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3537-40. PubMed ID: 11061497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort.
    Yoshimura N; Muraki S; Oka H; Kawaguchi H; Nakamura K; Akune T
    Mod Rheumatol; 2011 Dec; 21(6):608-20. PubMed ID: 21512822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R
    J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
    Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
    Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover.
    Srivastava AK; Libanati C; Hohmann O; Kriegman A; Baylink DJ
    Calcif Tissue Int; 2004 Dec; 75(6):477-81. PubMed ID: 15365658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
    Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
    J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.